search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Catheter ablation versus Amiodarone to pRevent Future ventricular tachycardia Episodes in patients with a defibrillator and a history of a myocardial infarction.


- candidate number9222
- NTR NumberNTR2802
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR11-mrt-2011
- Secondary IDs2011-001141-32 / 11.0333; EudraCT / METC
- Public TitleCatheter ablation versus Amiodarone to pRevent Future ventricular tachycardia Episodes in patients with a defibrillator and a history of a myocardial infarction.
- Scientific TitleCatheter ablation versus Amiodarone to pRevent Future ventricular tachycardia Episodes in patients with a defibrillator and a history of a myocardial infarction.
- ACRONYMCARFE 2
- hypothesisTime to recurrence of sustained VT (longer that 30 seconds or with hemodynamic instability) or VF with or without documented ICD therapy (shock or ATP) for VT of VF will be longer in patients randomized to substrate based ablation than in patients randomised to amiodarone.
- Healt Condition(s) or Problem(s) studiedMyocardial infarction, ICD shock, Sustained ventricle tachycardia
- Inclusion criteria1. Prior myocardial infarction, at least 3 months ago;
2. ICD implantation for any cause except for: Brugada syndrome, ARVC, HCM, LQTS, SQTS, cathecholaminergic polymorphic VT, other channelopathies;
3. ICD therapy (shock or ATP) for VT or VF without a reversible cause. Reversible causes (must be checked):
A. Acute myocardial ischemia in the following circumstances:
i. Acute coronary syndrome;
ii. Myocardial ischemia as documented by non-invasive myocardial ischemia testing what can be treated by revascularisation.
B. Whenever VT or VF occurs in the setting of antiarrhythmic medication intake (class I or III Vaughn-William) with increased QTc, the patient will not be a candidate for enrolment;
C. High fever (T>39 degrees Celsius) and signs of infection/sepsis at presentation will exclude patient from enrolment;
D. Lead dislocation on X-ray plus signs of mechanical VT induction will exclude patients from the study;
E. Other reversible causes as significant hypoxemia not caused by cardiac failure or known hyperthyroidism. Judgement whether this will be possible cause of VT/VF will be at discretion of the attending physician.
4. Optimal revascularization before ICD implantation performed;
5. Written informed consent.
- Exclusion criteria1. Age < 18 years;
2. Use of amiodarone more than 7 days before randomization within the period of 3 months before randomization. If a patient used amiodarone in preceding 3 months, the plasma levels of amiodarone and desethylamiodarone will be determined. If both levels are > 1mg/L the patient will be excluded from the study;
3. Inability to use amiodarone due to past side effects;
4. Class I antiarrythmic drugs not stopped ≤ 5 times ½T prior to randomization;
5. Protruding LV thrombus or cardiac tumor on pre-ablation echocardiogram;
6. Acute myocardial infarction within the preceding 3 months;
7. Non-reversible Class IV NYHA heart failure;
8. Valvular heart disease or mechanical heart valve precluding access to the left ventricle;
9. Unstable coronary artery syndrome or active myocardial infarction;
10. Cardiac surgery within the past 2 months;
11. Mechanical mitral or tricuspid valve prothesis;
12. Serum creatinine > 220 mmol/L (2.5 mg/dL);
13. Thrombocytopenia or coagulopathy;
14. Contraindication to anticoagulation;
15. Stroke within past 30 days;
16. Pregnancy;
17. Acute illness or serious active systemic infection;
18. Other disease process likely to limit survival to less than 12 months;
19. Lack of availability for follow-up.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-apr-2011
- planned closingdate1-apr-2016
- Target number of participants116
- InterventionsCatheter ablation or medical therapy with Amiodaron. Both interventions are already used in daily practice, but they have never been compared.
Amiodarone dosing: Starting dose:
1. Oral: 1 week 600mg per day, 1 week 400mg per day, afterwards 200mg per day;
2. Starting i.v.: 1200mg/24 hour loading dose and afterwards 200mg daily.
- Primary outcomeTime to recurrence of sustained VT (longer that 30 seconds or with hemodynamic instability) or VF with or without documented ICD therapy (shock or ATP) for VT of VF during the follow-up period starting post ablation or after receiving amiodarone.
- Secondary outcome1. Total number of ICD shocks during follow-up period;
2. Number of VT’s recorded by the ICD;
3. Quality of life (SF-36 score);
4. Number of hospital readmissions due to a cardiovascular indication;
5. Number of appropriate ICD therapies (including ATP);
6. Number of appropriate ICD shocks;
7. Number of inappropriate ICD therapies (including ATP);
8. Number of inappropriate ICD shocks;
9. Severe clinical events (death, syncope’s, electrical storm episodes (defined as > 3 sustained VT episodes within 24 hours) and cessation of amiodarone due to side-effects).
- TimepointsPatients will be seen by the investigator at baseline, 2, 6, 12, 18, 24 months and at 6 month intervals (at the discretion of the investigator) until completion of the follow up.
- Trial web sitewww.diagram-zwolle.nl
- statusstopped
- CONTACT FOR PUBLIC QUERIES J. Klijn
- CONTACT for SCIENTIFIC QUERIES J.J.J. Smit
- Sponsor/Initiator Isala Klinieken, Locatie Weezenlanden, Department of Cardiology
- Funding
(Source(s) of Monetary or Material Support)
Isala Klinieken, Maatschap Cardiologie
- PublicationsN/A
- Brief summaryThe primary purpose of this randomized study is the assessment of recurrences of sustained VT and ICD therapy for VT or VF after appropriate ICD therapy (ATP or shock) in patients with a history of a myocardial infarction undergoing substrate based ablation compared to patients treated with amiodarone alone. Thus the primary purpose is reduction of time to next appropriate ICD therapy or sustained VT.
- Main changes (audit trail)
- RECORD11-mrt-2011 - 16-jan-2012


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl